CliffBio
small molecule

PCE

ERYTHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand namePCE
Active ingredientERYTHROMYCIN
Strength500MG
Dosage formTABLET, COATED PARTICLES
RouteORAL
ModalitySmall molecule
FDA approvalAugust 1990
Marketing statusDISCN

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.